Arcus Biosciences, Inc. (RCUS)
21.95
+0.15
(+0.69%)
USD |
NYSE |
Jan 20, 16:00
22.21
+0.26
(+1.18%)
Pre-Market: 20:00
Arcus Biosciences EPS Diluted (Quarterly): -1.268 for Sept. 30, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Gilead Sciences, Inc. | 2.434 |
| Eli Lilly & Co. | 6.211 |
| Merck & Co., Inc. | 2.316 |
| Madrigal Pharmaceuticals, Inc. | -5.079 |
| Janux Therapeutics, Inc. | -0.392 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -135.00M |
| Revenue (Quarterly) | 26.00M |
| Total Expenses (Quarterly) | 161.00M |
| Enterprise Value | 1.996B |
| Gross Profit Margin (Quarterly) | 92.31% |
| Profit Margin (Quarterly) | -519.2% |
| Earnings Yield | -15.63% |
| Normalized Earnings Yield | -15.63 |